ADVERTISEMENT
LIVE DESK·Global markets desk·Last updated 14s ago
ADVERTISEMENT
Markets/EquitiesArticle

V2X growth chief appointed to NRO board

V2X Technologies' Chief Growth Officer joins the board of NRO, a subsidiary of Navistar, following shareholder approval.

PA
Priya Anand · Equities & Earnings Desk · 17 Aug 2026 · 1 min read
Share
V2X growth chief appointed to NRO board

V2X Technologies announced on Monday that its Chief Growth Officer, [Name], has been appointed as a director to the board of NRO, a wholly owned subsidiary of Navistar International Corporation.

The appointment follows a vote by NRO shareholders, who approved the addition of [Name] to the board during a meeting held last week. NRO, which specializes in integrated vehicle solutions, operates under the Navistar umbrella, a manufacturer of commercial trucks, buses, defense vehicles, and engines.

V2X Technologies, a provider of advanced defense and commercial vehicle technologies, did not disclose additional details regarding the scope of the director's responsibilities or the potential strategic implications of the appointment. The company emphasized that the move aligns with its broader growth initiatives and expansion into new markets.

Navistar International, headquartered in Lisle, Illinois, has not issued a separate statement regarding the appointment. The company’s shares were last seen trading at $68.45, up 1.2% in midday trading on Monday.

The development comes amid V2X’s ongoing efforts to strengthen its leadership team as it pursues opportunities in defense contracting and commercial vehicle innovation.

This article was produced with AI assistance and edited by a Finance Review Daily journalist.
ADVERTISEMENT
Novara — A Smarter Way to Access Global Markets
Share this story
PA
Written by
Priya Anand
Equities & Earnings Desk

Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.

More from Priya Anand →
ADVERTISEMENT
ADVERTISEMENT